[Approaches to the therapy of neurological presentations in diabetes mellitus].
A study included patients, aged from 30 to 70 years, with a verified diagnosis of compensated diabetes mellitus type 1 or type 2, diabetic polyneuropathy (DPN) or the syndrome of moderate cognitive disorders (MCD). Patients with DPN were stratified into two groups: 30 patients of the main group received the antioxidant drug tiolepta in tablets (600 mg) once a day during 60 days; 30 patients of the control group received only basic (sugar-reducing) therapy. Twenty patients with MCD were treated with the combined nootropic and vasoactive drug vinpotropil in dose 2 capsules, 3 times a day during 2 months in addition to the basic therapy (sugar-reducing, antihypertensive, antiaggregate drugs). To the end of treatment, the severity of DPN was lower in the main group treated with tiolepta that reflected in the normalization of NDS scores in 50% of patients compared to 30% in the controls and in the disappearance of neurological symptoms on the TSS in 30% of patients while these symptoms were present in the control group. The electroneuromyographic study showed the statistically non-significant trend (p>0,05) to the higher velocity of impulse conduction along the sensory and motor nerves as well as higher amplitudes of motor and sensory responses in the main group. To the end of the treatment, positive dynamics in the number of complaints and neurological status was found in patients with MCD. The neuropsychological study revealed the significant (p< or =0,05) improvement on the MMSE scale and in the delayed recall of words (the ten words test). Adverse effects that led to discontinuation of treatment were not found for both drugs.
Baratsevich
E R
ER
Posokhina
O V
OV
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006801:Humans; D008875:Middle Aged; D010889:Piracetam / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014748:Vinca Alkaloids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D028761:Withholding Treatment
D000975:Antioxidants; D004338:Drug Combinations; D014748:Vinca Alkaloids; C532690:piracetam, vinpocetine drug combination; D010889:Piracetam